Skye Bioscience (SKYE) Enterprise Value (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Enterprise Value of -$17.1 million for Q1 2026, up 71.11% year-over-year from -$10.0 million in Q1 2025, and up 33.53% quarter-over-quarter from -$25.7 million in Q4 2025.
Skye Bioscience (SKYE) Enterprise Value (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Enterprise Value for 15 consecutive years, with -$17.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 71.11% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at -$17.1 million (up 71.11% YoY), while the FY2025 annual figure was -$25.7 million, up 62.38% from the prior year.
- Enterprise Value climbed to -$17.1 million in Q1 2026 per SKYE's latest filing, from -$25.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4572.0 in Q1 2022 and bottomed at -$83.3 million in Q1 2024.
- Historically, Enterprise Value has averaged -$28.8 million across 5 years, with a median of -$17.1 million in 2026.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 99.91% — and 2024, when it plunged 1817233.34%.
- Skye Bioscience's Enterprise Value stood at -$4580.0 in 2022, then tumbled by 27333.47% to -$1.3 million in 2023, then plunged by 5345.15% to -$68.4 million in 2024, then jumped by 62.38% to -$25.7 million in 2025, then surged by 33.53% to -$17.1 million in 2026.
- Business Quant data shows SKYE's Enterprise Value at -$17.1 million in Q1 2026, -$25.7 million in Q4 2025, and -$35.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -10.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.11 Mn |
| Dec 31, 2025 | -25.74 Mn |
| Sep 30, 2025 | -35.31 Mn |
| Jun 30, 2025 | -48.59 Mn |
| Mar 31, 2025 | -59.22 Mn |
| Dec 31, 2024 | -68.42 Mn |
| Sep 30, 2024 | -67.41 Mn |
| Jun 30, 2024 | -74.12 Mn |
| Mar 31, 2024 | -83.34 Mn |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -9.08 Mn |
| Jun 30, 2023 | -553,443.00 |
| Mar 31, 2023 | -4,586.00 |
| Dec 31, 2022 | -4,580.00 |
| Sep 30, 2022 | -4,574.00 |
| Jun 30, 2022 | -4,573.00 |
| Mar 31, 2022 | -4,572.00 |
| Sep 30, 2021 | -4,570.00 |
| Jun 30, 2021 | -5.19 Mn |
| Mar 31, 2021 | -4,567.00 |